Eli Lilly testing Covid-19 antibody treatment with Vir Biotech's drug
The companies said on Wednesday that the collaboration marks the first time monoclonal antibodies from separate companies will be tested together
Eli Lilly and Co is testing its Covid-19 antibody therapy in combination with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline , in an effort to combat new variants of the coronavirus.
The companies said on Wednesday that the collaboration marks the first time monoclonal antibodies from separate companies will be tested together.
A study based on laboratory tests showed Covid-19 antibody drugs made by Eli Lilly may be less effective against a new coronavirus variant found in South Africa.
Keep updated, follow The Business Standard's Google news channel
"Adding VIR-7831 to our study is an important part of our commitment to develop therapies to treat current and future strains of Covid-19 until vaccines are widely available and utilized," Eli Lilly's Chief Scientific Officer Daniel Skovronsky said.
Lilly said on Tuesday it will move a new Covid-19 antibody therapy to human trials targeting the coronavirus variant that was first found in South Africa.
